ArticleAnimal bioscience2026
Resveratrol inhibits NLRP3 inflammasome activation to alleviate bovine mastitis by promoting PINK1-mediated mitophagy.
Article in Animal bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveNegative energy balance in transition cows elevates the circulating concentrations of non-esterified fatty acids (NEFA), potentially leading to mastitis and posing a significant threat to the dairy industry. Resveratrol is a polyphenolic compound with anti-inflammatory properties, yet its role in NEFA-induced inflammation in bovine mammary epithelial cells (BMECs) remains unclear. This study aimed how resveratrol protects against mastitis and its underlying mechanisms.
methodsBMECs were pre-treated with 100 μM resveratrol for 24 h, and then treated with 0.9 mM NEFAs for 4 h, and a PINK1 inhibitor was used to assess the mechanisms involved. Furthermore, a mouse model of mastitis was utilized to evaluate the hepatoprotective effects of resveratrol against mastitis in vivo.
resultsResveratrol significantly attenuated the NEFA-induced inflammatory response, evidenced by reduced levels of NLRP3 inflammasome components (NLRP3, caspase1, IL-1β) and pro-inflammatory cytokines (IL-6, IL-1β and TNF-α). Mechanistically, resveratrol promoted mitophagy by upregulating levels of LC3-II, PINK1, and Parkin, while downregulating P62 expression. The anti-inflammatory effect of resveratrol was reversed when PINK1 was inhibited. In vivo experiments confirmed that resveratrol alleviated mammary gland inflammation and enhanced PINK1-mediated mitophagy.
conclusionThis study demonstrates that resveratrol mitigates NLRP3-mediated inflammation by activating PINK1-mediated mitophagy, suggesting its potential as a therapeutic option for mastitis in perinatal dairy cows with negative energy balance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.